We investigated the effects of pharmacogenetic variations and efavirenz pharmacokinetics on inter-individual differences in the extent of CYP3A induction by efavirenz using 4b-hydroxycholesterol/cholesterol (4b-OHC/Chol) as a marker for CYP3A induction. Plasma 4b-hydroxycholesterol and cholesterol concentrations were determined at baseline, and at the 4th, 16th and 48th week of efavirenzbased highly active antiretroviral therapy in antiretroviral therapy-naive HIV patients (n ¼ 77). Efavirenz plasma concentrations were quantified at weeks 4 and 16. CYP2B6, CYP3A5, ABCB1, UGT2B7 genotyping were done. Compared with baseline, the median plasma 4b-OHC/Chol ratio increased at the 4th (257%), 16th (291%) and 48th (165%) week (Po0.0001). CYP2B6*6 genotype significantly influenced 4b-OHC/Chol ratio at weeks 16 (P ¼ 0.02) and 48 (P ¼ 0.04) being highest in CYP2B6*6/*64*1/*64*1/*1. There were positive correlations between plasma efavirenz and 4b-OHC/Chol ratios (week 4: P ¼ 0.02, week 16: P ¼ 0.001). CYP3A enzyme induction by efavirenz is pronounced in CYP2B6 slow metabolizers who have high efavirenz plasma exposure.
INTRODUCTION
4b-Hydroxycholesterol (4b-OHC) is a metabolite of cholesterol formed by CYP3A4/5. The ratio of plasma 4b-hydroxycholesterol/ cholesterol (4b-OHC/Chol) has attracted interest recently as an endogenous surrogate biomarker for CYP3A4/5 enzyme activity. Treatment of patients with inducers of CYP3A enzymes, including rifampicin and efavirenz, significantly increased concentrations of plasma 4b-OHC, whereas treatment with CYP3A inhibitors, such as ritonavir or itraconazole, resulted in decreased plasma concentrations. [1] [2] [3] [4] [5] Efavirenz was noted to increase the activities of CYP3A enzymes after a 10-day treatment course in healthy volunteers and a 4-week treatment in HIV patients. 1, 2 Efavirenz pharmacokinetics vary between healthy volunteers and HIV patients. 6 Efavirenz is a substrate and an inducer of CYP2B6, CYP3A and UGT2B7. The genes coding for these enzymes are polymorphic causing wide inter-individual variation in enzyme activity. Genetic variation in the ABCB1 gene influences efavirenz pharmacokinetics 7 and cellular cholesterol transport. 8 Plasma efavirenz concentration displays a wide between-patient variability partly due to ethnic and pharmacogenetic factors. 9 Therefore, interindividual variation in efavirenz exposure due to pharmacogenetic variations may influence the extent of enzyme induction. We recently reported that in HIV patients receiving efavirenz-based highly active antiretroviral therapy (HAART), the extent of efavirenz auto-induction is pronounced in CYP2B6 and UGT2B7 extensive metabolizers. [10] [11] [12] CYP3A induction by efavirenz is concentration-and time-dependent manner 1 and concomitant efavirenz therapy enhances the clearance of drugs metabolized by CYP3A. [13] [14] [15] However, the role of pharmacogenetic differences and efavirenz exposure in determining inter-individual variation in CYP3A induction/activity by efavirenz-based HAART remains to be investigated. Efavirenz treatment in HIV patients is life-long and hence its chronic use may have impact on long-term CYP3A induction and enzyme activity to cause potential drug-drug interactions and adverse events that may eventually affect treatment outcome. Therefore, characterization of the time course and magnitude of enzyme induction due to chronic efavirenz use may have clinical importance. The present study was designed to monitor the extent of CYP3A enzyme induction by efavirenz-based HAART in HIV patients without tuberculosis coinfection using 4b-OHC/Chol as a marker. We also explored whether the extent of change in CYP3A induction by efavirenz-based HAART is influenced by efavirenz pharmacokinetics and pharmacogenetic variations. We report that differences in the extent of CYP3A induction are partly explained by CYP2B6*6 genotype causing inter-individual variation in systemic efavirenz exposure in Ethiopian HIV patients.
MATERIALS AND METHODS

Study design and participants
This study was part of a multi-center project funded by European and Developing Countries Clinical Trial Partnership on optimization of HIV/TB cotreatment conducted at HIV clinics in Addis Ababa, Ethiopia. The study design was an open-label, repeated measure, prospective study to assess effects of efavirenz-based HAART on the change in CYP3A activity from baseline up to 48 weeks on therapy and evaluate pharmacogenetic and efavirenz pharmacokinetics as confounding factors. Newly diagnosed antiretroviral therapy-naive adult HIV-infected patients (n ¼ 77) with CD4 count o200 cells mm À 3 were enrolled prospectively and followed up to the 48th week of therapy. Institutional Review Boards of Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Addis Ababa University; and Ethiopian National Ethics Review Committee and Drug Administration and Control Authority of Ethiopia approved the study protocol. All procedures were carried out as per the recommendations of World Health Organization and International Conference for Harmonization Good Clinical Practice guidelines. All participants gave written informed consent.
Treatment and laboratory analysis
Patients received 600 mg efavirenz-based HAART containing either stavudine/lamivudine/efavirenz (d4T/3TC/EFV) or zidovudine/lamivudine/ efavirenz (ZDV/3TC/EFV). Pre-treatment CD4 count, HIV viral load, body mass index, plasma albumin, alanine transaminase, aspartate aminotransferase, total bilirubin, urea, hepatitis B and C virus, complete blood count with differentials and hemoglobin were determined. Treatment adherence was assessed by self-report and regularity to scheduled visits at the clinics.
Quantification of cholesterol and 4b-OHC Blood samples for determination of cholesterol and 4b-OHC were collected before starting therapy and during (weeks 4, 16 and 48) efavirenz-based HAART. Plasma samples were packed on dry ice and sent to the Division of Clinical Chemistry, Karolinska Institutet, Stockholm, Sweden for analysis. Cholesterol concentrations were measured by a commercial enzymatic method (Cholesterol CHOD-PAPP, Roche Diagnostics GmbH, Mannheim, Germany) run on a Roche/Hitatchi Modular instrument. The between-day variation was 1.3% (at 5 mmol l À 1 ). The determination of 4b-OHC was performed by isotope-dilution gas chromatography-mass spectrometry using deuterium-labeled 4b-OHC as an internal standard as described previously 16 and modified by Diczfalusy et al. 17 The relative between-day variation (CV) was 4.9% (at 26.5 ng ml 
Quantification of plasma efavirenz concentration
On the 4th and 16th week of efavirenz-based HAART, 8 ml of blood were collected from 68 patients 16 h post efavirenz dosing in a Vacutainer CPT (Becton Dickinson, Heidelberg, Germany), centrifuged (1700 g for 20 min) and a 2-ml plasma aliquot was stored at À 80 1C for the determination of efavirenz and its metabolite. Plasma samples were sent on dry ice to the Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany. The determination of plasma efavirenz and 8-hydroxyefavirenz by LC-MS/MS was performed as described previously. 10, 12 The lower limits of quantification in plasma were 10.0 ng ml À 1 for efavirenz and 0.4 ng ml À 1 for 8-hydroxyefavirenz. The efavirenz (8-hydroxyefavirenz) calibration range was 10-10 000 ng ml À 1 (0.4-400 ng ml À 1 ). The method was validated according to the FDA validation guidelines and fulfilled all criteria concerning accuracy, precision, recovery, linearity and stability.
Genotype analysis
Genomic DNA was isolated from peripheral blood leukocytes using QIAamp DNA Maxi Kit (QIAGEN GmbH, Hilden, Germany). Allelic discrimination reactions were performed using TaqMan (Applied Biosystems, Foster City, CA, USA) genotyping assays: (C__7586657_20 for ABCB1 3435C4T, C__7817765_60 for CYPB6 516G4T [CYP2B6*6], C__30720663_20 for UGT2B7 372G4A
[UGT2B7*2b,*2c,*2d,*2f], C__26201809_30 for CYP3A5 6986A4G [CYP3A5*3], C__30203950_10 for CYP3A5 14690G4A [CYP3A5*6]) and C__32287188_10 for CYP3A5 g.27131_27132insT [CYP3A5*7] on ABI 7500 FAST (Applied Biosystems). The final volume for each reaction was 10 ml, consisting of 2 Â TaqMan Universal PCR Master Mix (Applied Biosystems), 20 Â drug metabolizing genotype assay mix and 10 ng genomic DNA. The PCR profile consisted of an initial step at 50 1C for 2 min and 50 cycles with 95 1C for 10 min and 92 1C for 15 s.
Statistical analysis
Median (interquartile range) and proportions in percentage were used to describe baseline patient characteristics. Median (interquartile range) was used to describe plasma cholesterol, 4b-OHC concentrations and 4b-OHC/ cholesterol ratio before and during (weeks 4, 16 and 48) efavirenz-based HAART. w 2 Test was used to compare the observed and expected allele frequencies according to the Hardy-Weinberg equilibrium. Plasma efavirenz and 4b-OHC/Chol ratio were transformed into log 10 values for statistical analysis, and the Shapiro-Wilk test for normality was applied. The change in median 4b-OHC/Chol ratio over time was analyzed by the Friedman twoway analysis of variance (ANOVA). Dunn's multiple comparison test was used for pairwise comparison from baseline to week 48. Effect of sex and genotype on baseline plasma 4b-OHC/Chol ratio at each study time point was assessed using Kruskal-Wallis one-way ANOVA. Statistical analyses were performed using Statistica version 10 (StatSoftInc., Tulsa, OK, USA). A Po0.05 was considered significant. Graph Pad Prism version 5.0 for Windows (Graph Pad, La Jolla, CA, USA) was used for graphical presentations.
RESULTS
Patient characteristics
A total of 77 HIV patients (64 women and 13 men) were enrolled prospectively and followed up to 48 weeks. The median age of the study participants was 35 years (interquartile range 30-43 years). Plasma cholesterol and 4b-OHC concentrations were monitored in all patients before the start of therapy (week 0), and on the 4th, 16th and 48th weeks of therapy. Demographic and baseline biochemical variables of the study participants are presented in Table 1 .
Change in 4b-OHC/Chol ratio over time Concentrations of cholesterol, 4b-OHC and 4b-OHC/Chol ratios at baseline and at weeks 4, 16 and 48 are presented in Figure 1 . The percent change in the median 4b-OHC and 4b-OHC/Chol ratios Abbreviations: ALP, alkaline phosphatase; d4T30, stavudine 30 mg for patients weighingo60 kg; d4T40, stavudine 40 mg for patients weighing X60 kg; EFV, efavirenz; HAART; highly active antiretroviral therapy; Hb, hemoglobin; IQR, interquartile range; 3TC, lamivudine; WBC, white blood cell; ZDV, zidovudine.
CYP3A induction by efavirenz in HIV patients A Habtewold et al from baseline value is presented in Table 2 . At each follow-up time point, the percent change in plasma cholesterol, 4b-OHC and 4b-OHC/Chol ratios were calculated as concentration at week Â minus concentration at baseline (before treatment) divided by concentration at baseline, times 100. The median plasma 4b-OHC concentration was increased by 1.4-, 1.8-and 3.5-fold at weeks 4, 16 and 48, respectively. Overall compared with the baseline value, the median plasma 4b-OHC/Chol ratios increased by 2.6-, 2.9-and 1.7-fold at weeks 4, 16 and 48, respectively (Friedman two-way ANOVA test, Po0.0001). Dunn's multiple comparison test of pairwise contrast from baseline indicated a significant increase in the median 4b-OHC/Chol ratios (Po0.001) at each study time point (Table 2) . Despite the constant increase in 4b-OHC concentrations, the median plasma 4b-OHC/Chol ratio at week 48 was lower than at week 16 merely due to the relatively larger increase in the denominator cholesterol concentration.
Effect of sex, CYP2B6, CYP3A5, ABCB1 and UGT2B7 genotype The allele frequencies of CYP2B6*6, CYP3A5*3, CYP3A5*6, ABCB1-3435C4T and UGT2B7*2(-327G4A rs7662029) were 30.6, 66.9, 10.6, 21.3 and 46.7%, respectively. CYP3A5*7 was absent in all subjects. Haplotype analysis indicated no linkage disequilibrium between CYP3A5*3 and *6. Thus, participants were stratified based on the functional CYP3A5 allele (CYP3A5*1) for statistical analysis. There were no significant differences between the observed and expected genotype frequencies according to the Hardy-Weinberg equilibrium. Kruskal-Wallis one-way ANOVA was used to investigate effects of genotype on plasma 4b-OHC/Chol ratios at each time point. Influence of sex and genotype on plasma 4b-OHC/Chol ratio before starting efavirenz-based HAART and during therapy is presented in Table 3 . Mann-Whitney U-test indicated no significant effect of sex. None of the investigated genotypes including CYP3A5 had a significant effect except the CYP2B6 genotype whose influence became apparent and significant at weeks 16 and 48 but had no effect at baseline or at week 4. The within subject contrast test between adjacent concentrations indicated a significant effect of the CYP2B6 genotype on the change in 4b-OHC/Chol ratio (P ¼ 0.029, F ¼ 3.71). Friedman twoway ANOVA indicated that there were significant differences in the extent of change in 4b-OHC/Chol ratio over time between the different CYP2B6 genotypes; being highest in CYP2B6*6/*6 4*1/*64*1/*1 genotypes (Po0.04). The level increased significantly in carriers of the CYP2B6*6 allele at weeks 16 and 48. There was no effect of CYP3A5, ABCB1 or UGT2B7 genotype on the short-or long-term induction of CYP3A by efavirenz-based HAART.
Correlation between plasma efavirenz and 4b-OHC concentrations
In each study participant, we quantified plasma efavirenz concentration at weeks 4 and 16. There was a significant positive correlation between Log 4b-OHC/Chol ratio and Log plasma efavirenz concentration both at week 4 (P ¼ 0.02, r 2 ¼ 0.08) and at week 16 (P ¼ 0.001; r 2 ¼ 0.17 ( Figure 2) . The higher the plasma efavirenz concentration, the higher the respective 4b-OHC/Chol ratio.
DISCUSSION
In the present study we investigated effects of pharmacogenetic variations and efavirenz pharmacokinetics on inter-individual differences in the extent of CYP3A induction by efavirenz. 4b-OHC/Chol ratios were used as a marker for CYP3A induction. In each study participant, we monitored the change in 4b-OHC/Chol ratios from baseline up to 48 weeks on efavirenz therapy. Independent factors investigated for association were sex, plasma concentration of the inducer (efavirenz) and pharmacogenetic factors. 4b-OHC is a metabolite of cholesterol formed by CYP3A4/5. 17 Indeed plasma cholesterol concentration varied during efavirenz-based HAART (Table 2) . Therefore, determination of plasma 4b-OHC/Chol ratio could eliminate biases resulting from fluctuations in plasma cholesterol concentrations and can be used to follow the time course of CYP3A4/5 enzyme induction by inducers including efavirenz.
2,3,18
A previous study by Mouly et al. reported that efavirenz is an inducer of liver CYP3A4 in healthy volunteers, and inter-patient differences in magnitude of induction is partly explained by variation in systemic drug exposure. 1 In the present study in HIV patients being treated with efavirenz, we found a relatively week but statistically significant positive correlation between plasma efavirenz concentration and 4b-OHC/Chol ratio both at weeks 4 and 16 ( Figure 2) ; the higher the plasma efavirenz exposure, the higher the 4b-OHC/Chol ratio and hence the CYP3A induction. The contribution of variation in plasma efavirenz concentration in explaining the inter-individual variation in 4b-OHC/Chol ratios was only 8% at week 4 but become somewhat higher at week 16 (17%). Unfortunately, we did not determine plasma efavirenz concentration at week 48 to see whether the correlation between plasma efavirenz concentration and plasma 4b-OHC/Chol ratio would give an even higher r 2 value as therapy continues. However, we found significant influence of the CYP2B6*6 
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A Habtewold et al genotype on plasma 4b-OHC/Chol ratio at weeks 16 and 48 of efavirenz therapy. CYP2B6 is the major enzyme involved in the metabolism of efavirenz 19 and CYP2B6*6 is a variant allele known to be significantly associated with increased plasma efavirenz concentration. Accordingly the plasma 4b-OHC/Chol ratios were much higher particularly among carriers of the CYP2B6*6 allele in gene-dose dependent manner (Table 3) , being highest in slow metabolizers with CYP2B6*6/*6 genotype followed by *1/*6 and *1/*1. CYP3A induction by efavirenz is concentration-and time-dependent in humans. 1 Interestingly, the effect of CYP2B6 genotype on 4b-OHC/Chol ratios was significant only at weeks 16 and 48 but not at week 4 or at baseline. Evidently altered efavirenz plasma concentration during therapy is the mediator for the observed significant relationship between CYP2B6 genotype and extent of CYP3A induction. Efavirenz induces CYP2B6 and CYP3A enzymes reducing its own plasma Abbreviations: HAART; highly active antiretroviral therapy; IQR, interquartile range; 4b-OHC/Chol, 4b-hydroxycholesterol/cholesterol. 4b-OHC in ng ml The change in 4b-OHC to cholesterol Â 10 4 ratio over time using the Friedman two-way ANOVA.
CYP3A induction by efavirenz in HIV patients A Habtewold et al concentration over time mainly in extensive metabolizers having CYP2B6*1/*1 and *1/*6 genotypes. 11, 12 Paradoxically, elevated efavirenz plasma concentrations are observed particularly in CYP2B6*6*/*6 genotypes during long-term efavirenz-based HAART in HIV patients. 12, 20 Accordingly higher efavirenz plasma concentration is maintained for a longer period as a function of the CYP2B6*6/*6 genotype, resulting in pronounced long-term CYP3A induction. As to our knowledge this is the first study to report the influence of CYP2B6 genotype and systemic efavirenz plasma exposure on the extent of long-term CYP3A enzyme induction in HIV patients.
Previously, increased CYP3A enzyme activity in HIV patients after 4 weeks of efavirenz treatment was reported. 2 Our results indicate that the 4b-OHC/Chol ratio was significantly higher at all study time points (weeks 4, 16 and 48) than before the start of efavirenz-based therapy ( Figure 2 , Table 2 ), suggesting that CYP3A induction by efavirenz goes beyond week 4 and continues to rise up to 48 weeks. In contrast, full induction of CYP3A4 already is estimated to be achieved within 1-2 weeks after commencing treatment with rifampicin, a potent and strong CYP3A inducer. 21 None of our study participants were coinfected with tuberculosis and hence not cotreated with rifampicin, which enabled us to see the effect of efavirenz induction on CYP3A. It has been reported that cross-talk between the human pregnane and receptor (hP Â R), and the human constitutive androstane receptor (hCAR) results in shared transcriptional activation of CYP2B and CYP3A genes. 22 Rifampicin induces both CYP3A4/5 and CYP2B6 through the human nuclear receptor hP Â R, whereas efavirenz preferentially activates CYP2B6 and CYP3A4 to a lesser extent via hCAR. 23 This implies that rifampicin with its higher affinity to hP Â R has the capacity to mobilize all DNAresponsive elements for the induction of CYP3A4 in a short period of time compared with efavirenz, which exhibits preferential induction of CYP2B6 relative to CYP3A4 because of its weak binding and functional activation of CYP3A4. 22 Our results indicate that though relatively weak compared with rifampicin, efavirenz induction of CYP3A enzymes can be significant over time.
Our result in HIV patients is in line with previous reports where time-and concentration-dependent induction of CYP3A by efavirenz was noted in healthy volunteers 1 and in primary human hepatocytes. 24 The present study demonstrates that the CYP3A4 inductive effect by efavirenz prevails on long-term use, and hence the clearance of CYP3A4 substrates may increase considerably upon chronic efavirenz dosing in HIV patients. Efavirenz therapy in HIV patients is life-long. Therefore, characterization of the time course and extent of enzyme induction due to chronic efavirenz administration may ultimately lead to initially unanticipated antiretroviral drug interactions. Our finding indicates that CYP2B6 slow metabolizers might be at a higher risk for drug-drug interactions and adverse events. Recently, we reported an association of high efavirenz plasma concentration and the CYP2B6*6 allele with drug-induced liver injury. 25, 26 Long-term induction of CYP3A by chronic use of efavirenz in CYP2B6*6/*6 genotypes may result in rapid metabolism of concomitant drugs whose clearance is mainly dependent on CYP3A, causing low systemic plasma exposure. Actually cotreatment with efavirenz significantly lowers the plasma concentration of various drugs. 13, 15, 27 In the present study, we found no significant effect of ABCB1 3435C/T, CYP3A5, UGT2B7*2 genotypes or sex on plasma 4b-OHC/Chol ratio. We previously reported a significant influence of sex on CYP3A activity in healthy Ethiopians using 4b-OHC/Chol ratio as a marker 28 and also in healthy Ugandans using quinine as probe. 29 But we found no significant effect of sex and CYP3A5 genotype on 4b-OHC to cholesterol ratio in the present study, mainly because of the small number of study subjects and hence lack of power as there was only one individual homozygous for the functional CYP3A5*1 allele (Table 3) . Compared with other African populations, the frequency of the functional CYP3A5*1 allele is lower in Ethiopians. 10, 28, 29 Beside sample size differences, variation in the study population between our previous study in healthy volunteers and the present study in HIV patients may also contribute to the discrepant finding about sex and CYP3A5 genotype on plasma 4b-OHC/Chol ratio. Actually previous studies reported B50% lower CYP3A activity in HIVinfected patients compared with healthy volunteers, 30 and the need for cautious extrapolation of pharmacokinetic data from healthy volunteers to HIV patients is obvious. 6 However, the median 4b-OHC/Chol ratios before starting efavirenz therapy in HIV patients was comparable to what we reported from healthy Ethiopians previously.
In conclusion, we report that CYP3A enzyme induction during chronic use of efavirenz-based HAART in HIV patients is persistent up to week 48. The extent of CYP3A induction is pronounced mainly in patients with the CYP2B6*6/*6 genotype because of higher plasma efavirenz exposure. Inter-individual variation in plasma efavirenz exposure partly due to the CYP2B6 genotype may influence variability in the extent of CYP3A induction. Enduring use of efavirenz may result in unpredicted drug interactions upon concomitant administration of CYP3A substrates mainly in CYP2B6 slow metabolizers.
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